Data Sheet (Cat.No.T13295)

TargetMol
A DRUG SCREENING EXPERT

Veliflapon

Chemical Properties



CAS No.:	128253-31-6
Formula:	C23H23NO3
Molecular Weight:	361.43
Appearance:	N/A
Storage:	0-4℃ for short term (days to weeks), or -20℃ for long term (months).

Biological Description

Description	Veliflapon is an orally active and selective inhibitor of 5-lipoxygenase activating protein (FLAP). Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.
Targets(IC_{50})	LTB4: None
In vitro	Veliflapon inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice, and humans (IC50s: 0.026, 0.039, and 0.22 μM) as well as the formation of LTC4 with IC50 of 0.021 μM in mouse peritoneal macrophages stimulated with opsonized zymosan [3].
In vivo	Atherogenesis inhibited by Veliflapon (diet; 18.8 mg/kg/day for 16 weeks). In the arachidonic acid-induced mouse ear inflammation test, Veliflapon after topical (18 μg/ear) and oral (48.7 mg/kg) administration have anti-edematous effects. Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED40 of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay [4].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.767 mL	13.834 mL	27.668 mL
5 mM	0.553 mL	2.767 mL	5.534 mL
10 mM	0.277 mL	1.383 mL	2.767 mL
50 mM	0.055 mL	0.277 mL	0.553 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month. Please use it as soon as possible.

Reference

1. Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43(1-2):64-8.
2. Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7.
3. Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.
4. Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.

Tel:781-999-4286 E-mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481